Drug Profile
MPC 2130
Alternative Names: MPC-2130Latest Information Update: 26 Nov 2012
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class
- Mechanism of Action Apoptosis stimulants; Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Haematological malignancies